ReviewBone marrow transplantation2010
Going straight to the point: intra-BM injection of hematopoietic progenitors.
Review in Bone marrow transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Twenty-year follow-up of a randomized trial comparing intraosseous and i.v. BM transplantation.Bone marrow transplantation · 2014Trial
- Human Wharton's jelly-derived mesenchymal stromal cells promote bone formation in immunodeficient mice when administered into a bone microenvironment.Journal of translational medicine · 2023Article
- Cell therapies in the clinic.Bioengineering & translational medicine · 2021Review
- Bone Marrow Cell Trafficking Analyzed byClinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Superselective intra-arterial umbilical cord blood administration to BM in experimental animals.Bone marrow transplantation · 2014Article
- Irradiated allogeneic cells enhance umbilical cord blood stem cell engraftment in immunodeficient mice.Bone marrow transplantation · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intra-BM injection (IBMI) has been used clinically as a technique to deliver medications, blood products and fluids to critically ill children and war-wounded soldiers. Interest in IBMI has now been renewed in the setting of hematopoietic cell transplantation, in particular when umbilical cord blood is the graft source. Clinical studies have not yet unequivocally shown improvement in hematopoietic recovery. However, most intriguing is the observation, both in the clinical setting and in murine models, that the IBMI delivery of hematopoietic grafts and lymphocytes may reduce in the risk of acute GVHD. The underlying mechanism of the reduced risk of GVHD requires further investigation. In this study, we review the rationale as well as the clinical and pre-clinical data that support the study of IBMI as a method to deliver hematopoietic cells.
Indexed as
Identifiers
20305702What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.